How do the assisted reproductive technology (ART) outcomes of women presenting for
ART after cancer diagnosis compare to women without cancer?The likelihood of a live birth after ART among women with prior cancer using autologous
oocytes is reduced and varies by cancer diagnosis but is similar to women without
cancer when donor oocytes are used.Premenopausal patients faced with a cancer diagnosis frequently present for fertility
preservation.Population-based cohort study of women treated with ART in NY, TX and IL, USA.Women with their first ART treatment between 2004 and 2009 were identified from the
Society for Assisted Reproductive Technology Clinic Outcome Reporting System database
and linked to their respective State Cancer Registries based on name, date of birth
and social security number. Years were rounded, i.e. year 1 = 6-18 months before treatment.
This study used reports of cancer from 5 years, 6 months prior to treatment until
6 months after first ART treatment. Women who only presented for embryo banking were
omitted from the analysis. The likelihood of pregnancy and of live birth with ART
using autologous oocytes was modeled using logistic regression, with women without
prior cancer as the reference group, adjusted for woman's age, parity, cumulative
FSH dosage, infertility diagnosis, number of diagnoses, number of ART cycles, State
of residency and year of ART treatment. Results of the modeling are reported as adjusted
odds ratios (AORs) and (95% confidence intervals).The study population included 53 426 women; 441 women were diagnosed with cancer within 5 years prior to ART cycle start. Mean (±SD) age at cancer diagnosis was 33.4 ± 5.7 years; age at start of ART treatment was 34.9 ± 5.8 for women with cancer compared with 35.3 ± 5.3 years for women without cancer (P = 0.03). Live birth rates among women using autologous oocytes differed substantially by cancer status (47.7% without cancer versus 24.7% with cancer, P < 0.0001), and cancer diagnosis (ranging from 53.5% for melanoma to 14.3% for breast cancer, P < 0.0001. The live birth rates among women using donor oocytes did not vary significantly by cancer status (60.4% for women with any cancer versus 64.5% for women without cancer), or by cancer diagnosis (ranging from 57.9% for breast cancer to 63.6% for endocrine cancer). Women with breast cancer make up about one-third of all cancers in this cohort. Among women with breast cancer, 2.8% of the 106 women who underwent ART within 6 months of being diagnosed with cancer used donor oocytes compared with 34.8% of the 46 women who received ART treatment a longer time after being diagnosed with cancer (P < 0.0001). We conjecture that the former group were either unaware that they had cancer or decided to undergo ART therapy prior to cancer treatment. However, their live birth rate was only 11.7% compared with 28.8%, the overall live birth rate for all women with cancer using autologous oocytes (P < 0.0001). The live birth rate for women diagnosed with breast cancer more than 6 months before ART (23.3%) did not differ significantly from the overall live birth rate for cancer (P = 0.49). If this difference is substantiated by a larger study, it would indicate a negative effect of severe recent illness itself on ART success, rather than the poor outcome being only related to the destructive effects of chemotherapies on ovarian follicles. Alternatively, because of the short time difference between cancer diagnosis and ART treatment, these pre-existing cancers may have been detected due to the increased medical surveillance during ART therapy. In women who only used autologous oocytes, women with prior cancers were significantly less likely to become pregnant and to have a live birth than those without cancer (adjusted odds ratio (AOR): 0.34, [95% confidence interval (CI): 0.27, 0.42] and 0.36 [0.28, 0.46], respectively). This was also evident with specific cancer diagnoses: breast cancer (0.20 [0.13, 0.32] and 0.19 [0.11, 0.30], respectively), cervical cancer (0.36 [0.15, 0.87] and 0.33 [0.13, 0.84], respectively) and all female genital cancers (0.49 [0.27, 0.87] and 0.47 [0.25, 0.86], respectively). Of note, among women with cancer who became pregnant, their likelihood of having a live birth did not differ significantly from women without cancer (85.8 versus 86.7% for women using autologous oocytes, and 85.3 versus 86.9% for women using donor oocytes).Women may not have been residents of the individual States for the entire 5-year pre-ART
period, and therefore some cancers may not have been identified through this linkage.
As a result, the actual observed number of cancers may be an underestimate. In addition,
the overall prevalence is low due to the age distributions. Also, because we restricted
the pre-ART period to 5 years prior, we would not have identified women who were survivors
of early childhood cancers (younger than age 13 years at cancer diagnosis), or who
had ART more than 5 years after being diagnosed with cancer. Additional analyses are
currently underway evaluating live birth outcomes after embryo banking among women
with cancer prior to ART, cycles which were excluded from the analyses in this paper.
Future studies are planned which will include more States, as well as linkages to
vital records to obtain information on spontaneous conceptions and births, to further
clarify some of the issues raised in this analysis.Since the live birth rates using donor oocytes were not reduced in women with a prior
cancer, but were reduced with autologous cycles, this suggests that factors acting
in the pre- or peri-conceptional periods may be responsible for the decline.The study was funded by grant R01 CA151973 from the National Cancer Institute, National
Institutes of Health, USA. B.L. is a research consultant for the Society for Assisted
Reproductive Technology. All other authors report no conflict of interest.